Summary
74.76 0.76(1.03%)10/04/2024
Bio-Techne Corp (TECH)
Bio-Techne Corp (TECH)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.95 | -5.04 | 4.99 | 4.69 | 11.57 | 11.92 | -62.46 | 19,992.18 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 74.76 | |
| Open | 75.13 | |
| High | 75.74 | |
| Low | 74.05 | |
| Volume | 556,162 | |
| Change | 0.70 | |
| Change % | 0.95 | |
| Avg Volume (20 Days) | 573,825 | |
| Volume/Avg Volume (20 Days) Ratio | 0.97 | |
| 52 Week Range | 51.80 - 85.57 | |
| Price vs 52 Week High | -12.63% | |
| Price vs 52 Week Low | 44.32% | |
| Range | -0.49 | |
| Gap Up/Down | -2.29 | |
Fundamentals | ||
| Market Capitalization (Mln) | 12,380 | |
| EBIDTA | 323,364,992 | |
| PE Ratio | 45.1799 | |
| PEG Ratio | 1.1476 | |
| WallStreet Target Price | 80.55 | |
| Book Value | 12.4950 | |
| Earnings Per Share | 1.3900 | |
| EPS Estimate Current Quarter | 0.4100 | |
| EPS Estimate Next Quarter | 0.4900 | |
| EPS Estimate Current Year | 1.7700 | |
| EPS Estimate Next Year | 2.0400 | |
| Diluted EPS (TTM) | 1.3900 | |
| Revenues | ||
| Profit Marging | 0.1958 | |
| Operating Marging (TTM) | 0.1839 | |
| Return on asset (TTM) | 0.0632 | |
| Return on equity (TTM) | 0.1183 | |
| Revenue TTM | 1,144,999,040 | |
| Revenue per share TTM | 7.2630 | |
| Quarterly Revenue Growth (YOY) | 0.0040 | |
| Quarterly Earnings Growth (YOY) | -0.4520 | |
| Gross Profit (TTM) | 770,215,000 | |
| Dividends | ||
| Dividend Share | 0.3200 | |
| Dividend Yield | 0.0051 | |
| Valuations | ||
| Trailing PE | 45.1799 | |
| Forward PE | 33.6700 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 5.3420 | |
| Revenue Enterprise Value | 9.5279 | |
| EBITDA Enterprise Value | 29.0156 | |
| Shares | ||
| Shares Outstanding | 157,192,000 | |
| Shares Float | 155,394,984 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.04 | |
| Insider (%) | 0.97 | |
| Institutions (%) | 100.52 | |
10/02 15:30 EST - globenewswire.com
ALPHA PRO TECH, LTD. ANNOUNCES $1 MILLION EXPANSION OF SHARE REPURCHASE PROGRAM FOR IMMEDIATE RELEASE
NOGALES, Ariz., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Alpha Pro Tech, Ltd. (NYSE American: APT), a leading manufacturer of products designed to protect people, products and environments, including disposable protective apparel and building products, today announced that its Board of Directors has authorized a $1.0 million expansion of the Company's existing share repurchase program.
ALPHA PRO TECH, LTD. ANNOUNCES $1 MILLION EXPANSION OF SHARE REPURCHASE PROGRAM FOR IMMEDIATE RELEASE
NOGALES, Ariz., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Alpha Pro Tech, Ltd. (NYSE American: APT), a leading manufacturer of products designed to protect people, products and environments, including disposable protective apparel and building products, today announced that its Board of Directors has authorized a $1.0 million expansion of the Company's existing share repurchase program.
09/26 07:00 EST - prnewswire.com
LUNAPHORE PARTNERS WITH DISCOVERY LIFE SCIENCES TO BRING INNOVATIVE SPATIAL BIOLOGY SOLUTIONS TO CLINICAL RESEARCH
MINNEAPOLIS , Sept. 26, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that one of its spatial biology brands, Lunaphore, is partnering with Discovery Life Sciences (Discovery) to add Lunaphore COMET™, a best-in-class spatial biology platform, to Discovery's global suite of biospecimen products and specialty lab services supporting customers with clinical research.
LUNAPHORE PARTNERS WITH DISCOVERY LIFE SCIENCES TO BRING INNOVATIVE SPATIAL BIOLOGY SOLUTIONS TO CLINICAL RESEARCH
MINNEAPOLIS , Sept. 26, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that one of its spatial biology brands, Lunaphore, is partnering with Discovery Life Sciences (Discovery) to add Lunaphore COMET™, a best-in-class spatial biology platform, to Discovery's global suite of biospecimen products and specialty lab services supporting customers with clinical research.
09/24 07:00 EST - prnewswire.com
BIO-TECHNE TO PRESENT AT NEUROSCIENCE 2024-THE SOCIETY FOR NEUROSCIENCE (SfN) ANNUAL MEETING
MINNEAPOLIS , Sept. 24, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its portfolio of solutions advancing neuroscience research at the upcoming annual meeting of the Society for Neuroscience (SfN) at Neuroscience 2024, taking place October 5-9, 2024, in Chicago, Illinois.
BIO-TECHNE TO PRESENT AT NEUROSCIENCE 2024-THE SOCIETY FOR NEUROSCIENCE (SfN) ANNUAL MEETING
MINNEAPOLIS , Sept. 24, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its portfolio of solutions advancing neuroscience research at the upcoming annual meeting of the Society for Neuroscience (SfN) at Neuroscience 2024, taking place October 5-9, 2024, in Chicago, Illinois.
09/18 07:00 EST - prnewswire.com
ScaleReady announces a G-Rex® Grant has been awarded to ImmunoScape
ST. PAUL, Minn. , Sept. 18, 2024 /PRNewswire/ -- ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady™, today announced that ImmunoScape Pte.
ScaleReady announces a G-Rex® Grant has been awarded to ImmunoScape
ST. PAUL, Minn. , Sept. 18, 2024 /PRNewswire/ -- ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady™, today announced that ImmunoScape Pte.
09/18 07:00 EST - prnewswire.com
BIO-TECHNE ISSUES 2024 CORPORATE SUSTAINABILITY REPORT
MINNEAPOLIS , Sept. 18, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today issued its 2024 Corporate Sustainability Report (CSR), detailing the continued progress advancing its Environmental, Social and Governance (ESG) initiatives.
BIO-TECHNE ISSUES 2024 CORPORATE SUSTAINABILITY REPORT
MINNEAPOLIS , Sept. 18, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today issued its 2024 Corporate Sustainability Report (CSR), detailing the continued progress advancing its Environmental, Social and Governance (ESG) initiatives.
09/17 07:00 EST - prnewswire.com
Verismo Therapeutics Awarded a ScaleReady™ G-Rex® Grant
PHILADELPHIA , Sept. 17, 2024 /PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR T company developing the novel KIR-CAR platform technology, today announced that it has been awarded a $150,000 G-Rex Grant by ScaleReady™.
Verismo Therapeutics Awarded a ScaleReady™ G-Rex® Grant
PHILADELPHIA , Sept. 17, 2024 /PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR T company developing the novel KIR-CAR platform technology, today announced that it has been awarded a $150,000 G-Rex Grant by ScaleReady™.
09/17 07:00 EST - prnewswire.com
ScaleReady announces a G-Rex® Grant has been awarded to Verismo Therapeutics
ST. PAUL, Minn. , Sept. 17, 2024 /PRNewswire/ -- ScaleReadyTM, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH), and CellReadyTM, today announced that it has awarded a $150,000 G-Rex Grant to Verismo Therapeutics, a clinical-stage CAR T company developing the novel KIR-CAR platform technology.
ScaleReady announces a G-Rex® Grant has been awarded to Verismo Therapeutics
ST. PAUL, Minn. , Sept. 17, 2024 /PRNewswire/ -- ScaleReadyTM, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH), and CellReadyTM, today announced that it has awarded a $150,000 G-Rex Grant to Verismo Therapeutics, a clinical-stage CAR T company developing the novel KIR-CAR platform technology.
09/16 07:00 EST - prnewswire.com
ScaleReady and Bio-Techne Announce Optimal Closed System Cytokine Packaged for Single Step Use in Closed System G-Rex® Manufacture of CAR-T and TCR Therapies
ST. PAUL, Minn. , Sept. 16, 2024 /PRNewswire/ -- ScaleReady and Bio-Techne Corporation (NASDAQ: TECH) today announced the launch of the G-Rex optimized ProPakTM GMP Cytokines, ideally tailored to high efficiency closed system cell and gene-modified cell therapy (CGT) manufacturing.
ScaleReady and Bio-Techne Announce Optimal Closed System Cytokine Packaged for Single Step Use in Closed System G-Rex® Manufacture of CAR-T and TCR Therapies
ST. PAUL, Minn. , Sept. 16, 2024 /PRNewswire/ -- ScaleReady and Bio-Techne Corporation (NASDAQ: TECH) today announced the launch of the G-Rex optimized ProPakTM GMP Cytokines, ideally tailored to high efficiency closed system cell and gene-modified cell therapy (CGT) manufacturing.
09/12 21:15 EST - accesswire.com
ODDITY TECH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ODDITY Tech Ltd. - ODD
NEW ORLEANS, LA / ACCESSWIRE / September 12, 2024 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 17, 2024 to file lead plaintiff applications in a securities class action lawsuit against ODDITY Tech Ltd.
ODDITY TECH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ODDITY Tech Ltd. - ODD
NEW ORLEANS, LA / ACCESSWIRE / September 12, 2024 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 17, 2024 to file lead plaintiff applications in a securities class action lawsuit against ODDITY Tech Ltd.
09/11 22:08 EST - globenewswire.com
ODDITY TECH SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ODDITY Tech Ltd. - ODD
NEW ORLEANS, Sept. 11, 2024 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 17, 2024 to file lead plaintiff applications in a securities class action lawsuit against ODDITY Tech Ltd. (“Oddity” or the “Company”) (NasdaqGM: ODD), if they purchased the Company's securities between July 19, 2023 and May 20, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the Eastern District of New York.
ODDITY TECH SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ODDITY Tech Ltd. - ODD
NEW ORLEANS, Sept. 11, 2024 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 17, 2024 to file lead plaintiff applications in a securities class action lawsuit against ODDITY Tech Ltd. (“Oddity” or the “Company”) (NasdaqGM: ODD), if they purchased the Company's securities between July 19, 2023 and May 20, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the Eastern District of New York.
08/30 07:55 EST - zacks.com
New Strong Sell Stocks for August 30th
AMKR, TECH and CIADY have been added to the Zacks Rank #5 (Strong Sell) List on August 30, 2024.
New Strong Sell Stocks for August 30th
AMKR, TECH and CIADY have been added to the Zacks Rank #5 (Strong Sell) List on August 30, 2024.